Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Schering Fills Discovery-Development Gap Through Asian Partnering

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - Drug companies are tightening their belts for discovery and development while also scanning different sectors of the globe for innovation. Bayer Schering Pharma Head of Global Drug Discovery Andreas Busch sees outside partnerships, or "externalization," as a necessity, particularly for high-risk innovation, and Bayer is looking to Asia Pacific for many of its discovery partners

You may also be interested in...



Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So

SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt

Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So

SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt

Could "Calculated Risks" In China Help Solve Global R&D Challenges? Bayer Thinks So

Bayer Healthcare Chairman Jorg Reinhard says at BIO China that companies like Bayer must move away from their "comfort zone" and forge partnerships with Chinese companies.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC071154

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel